Clinical characteristics are better predictors of HRQOL in ESRD patients than socio-demographics in Singapore. Dialysis modality has no impact on the health utility of those patients.

NCS show better sensitivity than US in supporting a diagnosis of CTS. However, because of its high positive predictive value, one may consider using US as a screening test, eliminating the need for NCS in the majority of clinical suspicion of CTS and reserving NCS for cases in which US is negative.

A47 with ICD-9 diagnosis codes for stroke/TIA had their diagnostic imaging utilization summarized within ±3 days of the stroke/TIA event. Results: A total of 18,770 matched patients were identified; average age 65.5 (13.38 SD) and 21.9% female. When comparing patients that had at least one diagnostic procedure within the year, ICD patients had significantly less imaging overall [5.4 (6.38 SD) vs. 6.8 (8.18 SD), p< 0.0001]. Among patients with records of stroke/TIA (ICD 5%, non-implant 4%) and accompanying diagnostic imaging, 44% of non-implant patients underwent magnetic resonance imaging (MRI) vs. 1% of ICD patients (p< 0.0001) and had more imaging tests overall (4.1 (2.47 SD) vs. 3.2 (2.16 SD), p< 0.0001). ConClusions: MRI utilization is lower in ICD patients compared to non-implant patients. One in 20 ICD patients require imaging for a recorded stroke/TIA and less than 1% received MRI for this indication. The burden of incident stroke/TIA in contemporary ICD patients may justify consideration of MRI conditional devices in the majority of ICD patients.

A725Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted lifeyears (QALYs) were compared both in short term (2 years) and in long term (30 years). One-way and probabilistic sensitivity analyses were performed to test the robustness of the results. Results: Comparing to no tPA treatment, tPA treatment within 4.5 hours has a gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) per QALY gained after 2 years, and a lifetime gain of 0.422 QALYs at an additional cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY gained. Probabilistic sensitivity analysis shows that tPA treatment is cost-effective in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 16,200) per QALY. ConClusions: Intravenous tPA treatment within 4.5 hours is highly cost-effective for acute ischemic stroke in China setting.

p< 0.001), ranging to 13% with oxybutynin IR (HR 2.315; CI: 2.093−2.561; p< 0.001). Median number of days on therapy with mirabegron was 183 (treatment-experienced) and 129 (treatment-naïve), compared with 67−120 and 34−90 days with antimuscarinics, respectively. Mean adherence overall was 68% with mirabegron vs 39−55% with antimuscarinics (each p< 0.05 vs mirabegron). ConClusions: Patients treated with mirabegron had improved persistence and adherence over antimuscarinics. While differences in patient characteristics among the OAB drugs were accounted for within the model, results should be viewed in the light of the likely characteristics of patients started on any new medication to the market; hence this sample may not be reflective of more mature usage.objeCtives: The frequency of side effects in the treatment with anticholinergic drugs are well described in a number of previous studies. However, little is known about the impact of side effects on therapy discontinuation. The aim of the present study was to estimate the frequency of glaucoma in association with urinary incontinence therapy begin and the impact of glaucoma diagnosis on the therapy discontinuation based on real life data. Methods: Data from Disease Analyzer database including 988 general, 95 urologist and 203 gynecologist practices were used. 26,834 patients (17,125 female and 9,709 male) were identified to have received a first-time anticholinergic prescription of UI, namely darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine or trospium. Co-variates studied included demographic data, concomitant diagnoses and potential drug-induced side-effects. Glaucoma (H40) was defined as strict indication for the use of anticholinergic drugs. A Cox proportional hazard regression model was used to estimate the relationship between non-persistence and the diagnosis of glaucoma for up to 36 months. Results: The proportion of patients that were diagnosed with glaucoma during the time of treatment was very similar in each of the study substances. 32 -38 % of patients received a referral to an ophthalmologist and 0.3 -1.2 % of patients were first time diagnosed with glaucoma. Not surprisingly, there was a highly increased risk for treatment discontinuation in patients having glaucoma (HR: 1.46; p < 0.0001). ConClusions: Overall, the potential side effects including the aggravation of diagnosed glaucoma that were registered in the database were rarer than in clinical trials; most likely they were under-reported due to the nature of the registry. However, there was a significant impact of glaucoma on therapy discontinuation. This finding should be taken into account in clinical practice for the use of anticholinergic drugs in patients suffering from glaucoma.